Clinical Research Directory

Inclusion Criteria * Male or female patients, aged 15-40 years; * Single symptomatic osteochondral injury from OCD classified as ICRS OCD III or IV at the level of the femoral condyles; * Failure of conservative treatment * Lesion size between 1 and 10 cm2; * BMI ≤ 30; * Ability and consent of patients to actively participate in the rehabilitation protocol and clinical and radiological follow-up. Exclusion Criteria: * -Additional grade III or IV cartilage injury on the knee being treated; * Advanced osteoarthritis * Systemic or localized infection * Systemic (e.g. rheumatoid arthritis) or local (e.g. synovitis) inflammatory diseases and cardiovascular diseases * Immune system disorders * Degenerative or vascular bone pathology (e.g. osteonecrosis) * Coagulation disorders * Systemic conditions that alter wound healing * Established allergy to equine collagen and calcium phosphate salts * Presence of ligamentous/patellofemoral instability/malignment, varus or valgus malalignment ≤ 3° that cannot be treated/corrected simultaneously; * Previous tendon repair, ligamentous reconstruction, or realignment procedures within the past 12 months; * Presence of any known human immunodeficiency virus, hepatitis, syphilis, malignant neoplasms and ongoing anti-neoplastic chemotherapy and radiation treatment; Uncontrolled diabetes; Uncontrolled thyroid function changes; Uncontrolled metabolic disorders; Renal disease and hypercalcemia * Uncooperative patients, including those with a history of alcohol and drug abuse; Participation in another clinical trial or medical device trial that clinically interferes with the present pilot study; * Incapacitated patients; * Pregnant or lactating women. In particular, in the case of a suspected pregnancy in a patient of childbearing age, this will be excluded by serological testing (hCG).